A 12-Week Randomized, Double-Blind, Placebo-Controlled Study of Baicalin in the Treatment of Drug-Induced Obesity in Schizophrenia

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000032766

Enrollment

Unknown

Registered

2020-05-09

Start date

2020-05-09

Completion date

Unknown

Last updated

2020-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

A:Placebo

B:baicalin 0.5g, tid, po.

C:baicalin 0.75g, tid, po.

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: (1) male or female patients; (2) age range: 18-55 years old; (3) dsm-iv diagnostic criteria: schizophrenia; (4) weight gain was significant after previous or current antipsychotic treatment, and BMI >= 25; (5) voluntarily participate in signing the informed consent.

Exclusion criteria

Exclusion criteria: (1) a history of substance dependence, or psychotic symptoms caused by other mental disorders; (2) having brain trauma, epilepsy or other organic brain diseases; (3) those who have suicidal attempts or thoughts; (4) those who are receiving antidepressants, mood stabilizers or electroconvulsive therapy; (5) laboratory tests showed liver and kidney function impairment or other serious physical diseases and metabolic disorders; (6) pregnant women or lactating patients.

Design outcomes

Primary

Measure	Time frame
Serum lipid level;Fasting glucose;fasting insulin;weight;BMI;Waist circumference;Hip circumference;	—

Secondary

Measure	Time frame
Intestinal flora;Metabolic indices;Blood inflammatory index;Index of oxidative stress;PANSS score;TMAO;	—

Countries

China

Contacts

Public ContactXueqin Song

The First Affiliated Hospital of Zhengzhou University

sxqzhll@126.com+86 13513895052

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026